Medigene AG Shares Downgraded to General Standard on Frankfurt Stock Exchange Following Insolvency Proceedings
MediGene AG, an oncology company, has been downgraded from the Prime Standard to the General Standard segment on the Frankfurt Stock Exchange following preliminary insolvency proceedings initiated on April 24, 2024. This downgrade allows the company's shares to continue trading under the same stock identification while it aims to stabilize operations and focus on cancer research and development.
MediGene AG, an oncology platform company specializing in T cell receptor-guided therapies for cancer treatment, is undergoing significant changes following preliminary insolvency proceedings initiated by the Munich Local Court on April 24, 2024. As part of the restructuring process, the Frankfurt Stock Exchange has downgraded the company’s shares from the Prime Standard segment to the General Standard segment. This move, effective immediately, allows Medigene AG’s shares to continue trading under the same stock identification in the regulated market. The company is navigating these proceedings with the aim of stabilizing its operations and continuing its focus on cancer research and development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediGene AG published the original content used to generate this news brief on June 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
